Last April we reported on Pimavenserin – Nuplazid – the novel antipsychotic that’s FDA approved in psychosis related to parkinson’s disease. In that article we mentioned a randomized controlled trial from Mass General – the CLARITY trial - that showed promising augmentation effects when Pimavenserin was added to an antidepressant in major depressive disorder. Now comes a secondary analysis of that study, which found a significant reduction in anxiety symptoms as well. [Link (https://journals.lww.com/intclinpsychopharm/Fulltext/2020/11000/Effect_of_pimavanserin_on_anxious_depression_in.4.aspx) and Link (https://pubmed.ncbi.nlm.nih.gov/32174828/)]
Published On: 10/21/2020
Duration: 3 minutes, 9 seconds
Got feedback? Take the podcast survey. (http://www.thecarlatreport.com/podcastsurvey)

Two Updates on Pimavenserin [60 Sec Psych]

Clear, engaging, and practical updates on clinical psychiatry. Hosted by Chris Aiken, MD, and Kellie Newsome, PMHNP.    
Earn CME for listening at www.thecarlatreport.com/podcastcme

Alternative Health

Health

Medicine

Science & Medicine

Health & Fitness

Mental Health

What steps should clinicians take if psychopharmacologic treatments and school behavioral strategies are insufficient for managing a child with ADHD? We've all been there. ADHD, attention deficit hyperactivity disorder, of course, affects millions of children and adolescents worldwide and can significantly impact focus, impulses, and engagement with friends.Parents and caregivers need to understand the different kinds of medications and therapies that are available to help manage ADHD. In this podcast, Mara and I will explore the various treatment options for ADHD in children and discuss how to navigate the process of selecting more effective treatments.﻿Published On: 04/22/2024Duration: 26 minutes, 43  secondsJoshua Feder, MD, and Mara Goverman, LCSW, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

ADHD Algorithm

In today's episode, Dr. Brian Hurley provides expert insights into the current state of stimulant use disorder, its implications across different regions, and available treatment options. CME: Take the CME Post-Test for this EpisodePublished On: 04/15/2024Duration: 30 minutes, 43 secondNoah Capurso, MD, Brian Hurley, MD have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Stimulant Update with Dr. Brian Hurley

Does psychiatry keep making the same mistakes? Edward Shorter gives us a historical perspective. CME: Take the CME Post-Test for this EpisodePublished On: 04/08/2024Duration: 22 minutes, 16 secondChris Aiken, MD, Edward Shorter, PhD and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Controversies in Psychiatry

Viibryd has gone generic, but is it worth prescribing? We review all there is to know about vilazodone in this update from our #1 most read article of 2023.CME: Take the CME Post-Test for this EpisodePublished On: 04/01/2024Duration: 12 minutes, 47 secondChris Aiken, MD, and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Viibryd Goes Generic

All sorts of medications are prescribed for anxiety in older adults. Today, we look at when and how to discontinue them.CME: Take the CME Post-Test for this EpisodePublished On: 03/25/2024Duration: 22 minutes, 47 secondChris Aiken, MD, and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Two Updates on Pimavenserin [60 Sec Psych]

Download our free app to listen on your phone